Highly regioselective bromination reactions of polymethylpyrimidines
摘要:
4,5-Dimethyl- and 4,5,6-trimethyl-substituted pyrimidines are brominated at C5-Me with NBS in CCl4 and at C4(6)-Me with bromine in acetic acid to give the corresponding bromomethyl derivatives in a high yield. The remaining methyl group(s) can also be brominated with high regioselectivity. The 2-methylthio substituent is not oxidized under these conditions.
reported here the low loading porphyrin-inspired high-valent manganese (IV)-oxo complex was applied in oxidative kineticresolution (OKR) of racemic heterocyclic sulfoxides using the environmentally benign hydrogen peroxide for the first time. This approach allows for rapid OKR (0.5 h) of a variety of racemic sulfoxides (including pyridine, pyrimidine, pyrazine, thiazole, benzothiazole, thiophene) in
2-Aminopyrimidine derivatives and their medical use
申请人:Bollbuck Birgit
公开号:US20070043048A1
公开(公告)日:2007-02-22
A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.
Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
申请人:Incyte Corporation
公开号:US20140221379A1
公开(公告)日:2014-08-07
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I:
which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.